SkinBioTherapeutics PLC on Friday said it has received approval from regulators to sell AxisBiotix-Ps, a food supplement designed to treat symptoms of psoriasis, to consumers in France.

The Newcastle-based life science company, which is focused on skin health, said it expects to start marketing the product in France in October.

Chief Executive Officer Stuart Ashman commented: ‘In line with our strategic plan, we are delighted that AxisBiotix-Ps is now approved for sale in another market...We anticipate an open reception from potential new customers in our European markets due to their positive attitude to food supplements.’

SkinBio said psoriasis, which causes flaky and scale-like patches of skin to form, affects between 2% and 3% of the global population, with around two million sufferers in France. It said the AxisBiotix-Ps food supplement, which re-introduces the necessary gut bacteria to improve skin health, can be used over long periods unlike existing psoriasis treatments such as steroids.

SkinBio previously gained regulatory approval in March to sell AxisBiotix-Ps in Spain, followed by Italy in June. The product is also available in the UK.

On Friday SkinBio said it is in talks with other European regulators to expand the supplement’s availability, but has not yet confirmed its next target country for launch.

Ashman said: ‘We have now completed the goal of launching in three major European markets in 2023 and we look forward to updating the market on other country launches next year.’

SkinBioTherapeutics shares were up 3.2% at 22.70 pence in London on Friday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.